|
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer Clinical research trials and Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer. Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer clinical trial. Subjects often receive the most expert healthcare possible for their Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer  Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
For Condition: Muscle Cancer,Neuroblastoma,Osteosarcoma,childhood soft tissue sarcoma
Status: No longer recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody A1G4 with BCG may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody A1G4 plus BCG in treating patients with cancer.
Details: OBJECTIVES: - Assess the toxicity and feasibility of immunizing patients with anti-idiotypic rat monoclonal antibody A1G4 combined with Bacillus Calmette Guerin (BCG) adjuvant. - Determine whether immunization with A1G4 combined with BCG results in an immune response directed against GD2 ganglioside in patients. OUTLINE: All patients are treated with A1G4 diluted in sterile physiologic saline mixed with Bacillus Calmette Guerin (BCG) organisms. The vaccine is injected intradermally in multiple sites. Booster immunizations are administered during weeks 2, 4, 8, 12, 20, 28, 36, 44, 52. Immunizations are not administered in limbs where draining lymph nodes have been surgically removed or previously irradiated. Isoniazid is administered for 5 days after each BCG injection. If severe skin reactions are present at the injection site, the BCG dose is decreased. If skin reactions persist, the BCG dose is stopped but A1G4 injections continue. At least 6 patients are accrued at each dose level of A1G4. Dose escalation is not carried out until patients have been followed for at least 8 weeks after the first immunization without encountering grade 3 or worse non-skin toxicity. If 0-1 patient experiences dose limiting toxicity (DLT) at a given dose level, then patients are accrued to the next higher dose level. If 2 or more patients experience DLT, the MTD is defined as the previous dose level. Patients are followed for at least 1 year. PROJECTED ACCRUAL: A total of 24 patients are expected to complete this study. If patients are removed early from the study prior to evaluation for serological response, additional patients will be accrued until 6 patients are evaluable for serological response.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed GD2 positive tumors which include: - High risk neuroblastoma (stage IV, or N-myc amplified, or localized neuroblastoma multiply recurrent) - Recurrent or metastatic osteosarcoma - Recurrent or metastatic GD2 positive sarcomas - If free of disease, patient must be fully recovered from toxic effects or complications of prior treatments (chemotherapy or surgery) - No greater than 6 months since last chemotherapy or surgery before first injection of A1G4 PATIENT CHARACTERISTICS: Age: - Any age Performance status: - Not specified Life expectancy: - At least 6 months Hematopoietic: - Absolute neutrophil count greater than 500/mm^3 - Absolute leukocyte count greater than 500/mm^3 - Peripheral T-cell phytohemagglutinin activation (PHA) at least 50% of normal Hepatic: - Not specified Renal: - Not specified Cardiovascular: - No significant heart disease (NYHA class III or IV) Other: - No other serious intercurrent illnesses - No active infections requiring antibiotics - No active bleeding - No primary immunodeficiency - Not pregnant or nursing - Adequate contraception required of all fertile patients PRIOR CONCURRENT THERAPY: Biologic therapy: - No concurrent antibiotics - No prior mouse antibodies and detectable human antimouse antibody (HAMA) titer Chemotherapy: - See Disease Characteristics - At least 6 weeks since nitrosoureas - At least 4 weeks since other systemic chemotherapy Endocrine therapy: - No concurrent nonsteroidal anti-inflammatory agents - No concurrent corticosteroid Radiotherapy: - At least 4 weeks since radiotherapy - No prior radiation therapy to the spleen Surgery: - See Disease Characteristics - No splenectomy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
Nai-KongCheung, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: CDR0000065609; MSKCC-97024,NCI-G97-1268
Study Start Date:
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003023
Other Neuroblastoma Studies:
1. Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
2. Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
3. Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
4. Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma
5. Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
Related Studies:
Other Neuroblastoma Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
|
|
|
|
|
|
|
|
